Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
Overcoming the limits: bringing CAR T-cell therapy to the masses
iwCLL 2017 program: the biology of CLL, treatment options and the relapsed/refractory setting
Combining CLL drugs to overcome the problem of resistance
Supporting young hematology researchers: training programs offered by EHA and ASH